Product Design & Development

Covidien says FDA extends Exalgo review

By The Associated Press
Friday, November 20, 2009

 Share
[-] Text [+]  
Loading...

Covidien says FDA extends Exalgo review

Health care company Covidien PLC said Friday the Food and Drug Administration will take longer than expected to review the potential opioid pain drug Exalgo.

The agency said it is delaying a decision on the treatment by three months, to Feb. 22. The FDA was scheduled to make a decision by Nov. 22, but the company sent in additional information on the drug candidate. That prompted the three-month extension by the agency.

In June, Ireland-based Covidien bought the rights to Exalgo from Neuromed Pharmaceuticals Ltd. for an undisclosed amount.

Shares of Covidien fell 14 cents to $45 in morning trading.

ADVERTISEMENT

JOIN THE DISCUSSION
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

At Issue

Risky Business: Funding Medical Device Innovation
Rahul Sathe, Principal Mechanical Engineer, Surgical and Interventional Products, Cambridge Consultants
Extracting Nuggets from the Invention Mine
Tom Tuytschaevers, a member of our Patent Practice Group

Site Sponsors


Most Viewed

Videos & Webcasts

The Energy Miser Concept Home 2/8/2012
Lower energy bills while making the house more comfortable, quieter, and safer? Who cares when you're demonstrating a completely Apple-based home control and automation system.   Continue
Inside the Audi A7 2/8/2012
When you take a look at the GPS system, you see real-time Google Earth 3D image navigation rather than cartoon-colored maps. It also powers the night vision system which includes a thermal camera to help detect pedestrians.   Continue
Engineering Mind Challenge Solved 2/8/2012
Dan and Vince find the solution to last week’s question "will the fan blade hit me if I try to stick my head between the spinning blades?"   Continue

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter